THU0042 EFFECT OF SPLEEN TYROSIN KINASE (SYK)-INHIBITORS ON RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.4865
Abstract: Background: The spleen tyrosine kinase (syk) is an intracellular protein kinase involved in signal transmission processes of immune cells and non-hematopoietic cells, such as fibroblasts. Various syk-inhibitors are therefore currently being tested in preclinical and… read more here.
Keywords: tak 659; kinase; rasf; effect ... See more keywords
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-3239
Abstract: Purpose: TAK-659 is an investigational, dual SYK/FLT3 inhibitor with preclinical activity in B-cell malignancy models. This first-in-human, dose-escalation/expansion study aimed to determine the safety, tolerability, MTD/recommended phase II dose (RP2D), and preliminary efficacy of TAK-659… read more here.
Keywords: tak 659; 659 investigational; cell lymphoma; investigational dual ... See more keywords
Abstract 3039: Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Tumor Biology"
DOI: 10.1158/1538-7445.am2021-3039
Abstract: Introduction: While children with acute lymphoblastic leukemia (ALL) experience close to a 90% likelihood of cure, the outcome for certain high-risk pediatric ALL subtypes remains poor. Spleen Tyrosine Kinase (SYK), a cytosolic nonreceptor tyrosine kinase,… read more here.
Keywords: leukemia; lineage; tak 659; syk flt3 ... See more keywords
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Haematologica"
DOI: 10.3324/haematol.2022.281216
Abstract: Mivavotinib (TAK-659) is an investigational type 1 tyrosine kinase inhibitor with dual activity against spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 (FLT3). We conducted a phase Ib study to investigate the safety, tolerability,… read more here.
Keywords: myeloid leukemia; mivavotinib tak; mivavotinib; acute myeloid ... See more keywords